Morgan Stanley Lava Therapeutics Nv Call Options Transaction History
Morgan Stanley
- $1.35 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding LVTX
# of Institutions
28Shares Held
3.61MCall Options Held
32.9KPut Options Held
500-
Redmile Group, LLC San Francisco, CA2.07MShares$3.32 Million0.23% of portfolio
-
Bruce & Co., Inc. Chicago, IL772KShares$1.23 Million0.53% of portfolio
-
Sphera Funds Management Ltd. Tel Aviv, L3146KShares$234,3310.04% of portfolio
-
Two Sigma Investments, LP New York, NY103KShares$164,4250.0% of portfolio
-
Pathway Financial Advisors LLC103KShares$164,0000.04% of portfolio
About LAVA Therapeutics NV
- Ticker LVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,797,700
- Market Cap $41.3M
- Description
- LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer...